Anticancer drug 5-fluorouracil induces reproductive and developmental defects in Caenorhabditis elegans

Reproductive Toxicology

Volumn 29, Issue 4, 2010, Pages 415-420

  Kumar, Sandeep ^a,b   Aninat, Caroline ^a,b   Michaux, Grégoire ^b   Morel, Fabrice ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

5 Fluorouracil; Caenorhabditis elegans; Development; Egg hatching; Vulva

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LIN 29; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE; ANTINEOPLASTIC ANTIMETABOLITE; CAENORHABDITIS ELEGANS PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CELL CYCLE ARREST; CHRONIC TOXICITY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; EGG LAYING; EMBRYO; EMBRYO DEVELOPMENT; GENE REPRESSION; GERM LINE; GONAD DEVELOPMENT; HATCHING; MUSCLE DEVELOPMENT; NONHUMAN; REPRODUCTIVE TOXICITY; RNA INTERFERENCE; VULVA; ANIMAL; ANIMAL EMBRYO; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; TOXICITY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; DISEASE MODELS, ANIMAL; EMBRYO, NONMAMMALIAN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE SILENCING; OVIPOSITION; RNA INTERFERENCE; RNA, SMALL INTERFERING; URACIL-DNA GLYCOSIDASE; VULVA;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 77953540951     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2010.02.006     Document Type: Article

References (32)

1. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
2. Hrushesky W.J., Vyzula R., Wood P.A. Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reprod Toxicol 1999, 13:413-420.
3. Naya M., Mataki Y., Takahira H., Deguchi T., Yasuda M. Effects of phorone and/or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice. Teratology 1990, 41:275-280.
4. Russell L.D., Russell J.A. Short-term morphological response of the rat testis to administration of five chemotherapeutic agents. Am J Anat 1991, 192:142-168.
5. Paskulin G.A., Gazzola Zen P.R., de Camargo Pinto L.L., Rosa R., Graziadio C. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 2005, 73:634-637.
6. Santi D.V., McHenry C.S., Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13:471-481.
7. Kim S., Park D.H., Shim J. Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans. Mol Cells 2008, 26:344-349.
8. Kim S., Park D.H., Kim T.H., Hwang M., Shim J. Functional analysis of pyrimidine biosynthesis enzymes using the anticancer drug 5-fluorouracil in Caenorhabditis elegans. FEBS J 2009, 276:4715-4726.
9. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974, 77:71-94.
10. Sulston J.E., Schierenberg E., White J.G., Thomson J.N. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol 1983, 100:64-119.
11. Kim S., Shim J. A forward genetic approach for analyzing the mechanism of resistance to the anti-cancer drug, 5-fluorouracil, using Caenorhabditis elegans. Mol Cells 2008, 25:119-123.
12. Dengg M., Garcia-Muse T., Gill S.G., Ashcroft N., Boulton S.J., Nilsen H. Abrogation of the CLK-2 checkpoint leads to tolerance to base-excision repair intermediates. EMBO Rep 2006, 7:1046-1051.
13. Kosovec J.E., Egorin M.J., Gjurich S., Beumer J.H. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2008, 22:224-230.
14. Kelly K.O., Dernburg A.F., Stanfield G.M., Villeneuve A.M. Caenorhabditis elegans msh-5 is required for both normal and radiation-induced meiotic crossing over but not for completion of meiosis. Genetics 2000, 156:617-630.
15. Kamath R.S., Martinez-Campos M., Zipperlen P., Fraser A.G., Ahringer J. Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol 2001, 2. RESEARCH0002.
16. Timmons L., Court D.L., Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene 2001, 263:103-112.
17. Sternberg P.W., Horvitz H.R. Pattern formation during vulval development in C. elegans. Cell 1986, 44:761-772.
18. Weidhaas J.B., Eisenmann D.M., Holub J.M., Nallur S.V. A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death. Proc Natl Acad Sci U S A 2006, 103:9946-9951.
19. Ririe T.O., Fernandes J.S., Sternberg P.W. The Caenorhabditis elegans vulva: a post-embryonic gene regulatory network controlling organogenesis. Proc Natl Acad Sci U S A 2008, 105:20095-20099.
20. Bettinger J.C., Euling S., Rougvie A.E. The terminal differentiation factor LIN-29 is required for proper vulval morphogenesis and egg laying in Caenorhabditis elegans. Development 1997, 124:4333-4342.
21. Newman A.P., Inoue T., Wang M., Sternberg P.W. The Caenorhabditis elegans heterochronic gene lin-29 coordinates the vulval-uterine-epidermal connections. Curr Biol 2000, 10:1479-1488.
22. Rougvie A.E., Ambros V. The heterochronic gene lin-29 encodes a zinc finger protein that controls a terminal differentiation event in Caenorhabditis elegans. Development 1995, 121:2491-2500.
23. Trent C., Tsuing N., Horvitz H.R. Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics 1983, 104:619-647.
24. Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006, 18:321-324.
25. Shehata N., Pater A., Tang S.C. Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Cancer Invest 1999, 17:201-205.
26. Guillet M., Boiteux S. Origin of endogenous DNA abasic sites in Saccharomyces cerevisiae. Mol Cell Biol 2003, 23:8386-8394.
27. Fischer F., Baerenfaller K., Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007, 133:1858-1868.
28. Seiple L., Jaruga P., Dizdaroglu M., Stivers J.T. Linking uracil base excision repair and 5-fluorouracil toxicity in yeast. Nucleic Acids Res 2006, 34:140-151.
29. Stergiou L., Hengartner M.O. Death and more: DNA damage response pathways in the nematode C. elegans. Cell Death Differ 2004, 11:21-28.
30. Patterson G.I., Padgett R.W. TGF beta-related pathways. Roles in Caenorhabditis elegans development. Trends Genet 2000, 16:27-33.
31. Fukuchi S.G., Seeburger J.L., Parquet G., Rolandelli R.H. Influence of 5-fluorouracil on colonic healing and expression of transforming growth factor-beta 1. J Surg Res 1999, 84:121-126.
32. Wendling J., Marchand A., Mauviel A., Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 2003, 64:707-713.